

12-17-99

PATENT APPLICATION TRANSMITTAL LETTER

Attorney Docket No.  
RPP:156B US

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Transmitted herewith for filing is the patent application of

**Yasmin Thanavala and Charles Joel Arntzen**

for

**ORAL IMMUNOLOGY USING PLANT PRODUCT  
CONTAINING A NON-ENTERIC PATHOGEN ANTIGEN**

Enclosed are:


- [ X ] Certificate of Mailing with Express Mail Mailing Label No. EJ870782822US
- [ ] \_\_\_\_\_ sheets of drawing(s)
- [ ] a certified copy of a \_\_\_\_\_ application
- [ X ] Declaration and Power of Attorney (unsigned)
- [ ] \_\_\_\_\_ Verified Statement(s) Claiming Small Entity Status

CLAIMS AS FILED				
For	Number Filed	Number Extra	Rate	Fee
TOTAL CLAIMS	12 - 20 =	0	x \$9	0.00
INDEPENDENT CLAIMS	1 - 3 =	0	x \$39	0.00
BASIC FEE				\$ 380.00
TOTAL FILING FEE				380.00

- [ ] Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_. A duplicate copy of this sheet is enclosed.
- [ X ] A check in the amount of \$380.00 to cover the filing fee is enclosed.
- [ X ] The Commissioner is hereby authorized to charge any additional fees which may be required at any time during the prosecution of this application without specific authorization, including those which may be due under 37 C.F.R. 1.16, 1.17, 1.18 and 1.20, or credit any overpayment to Deposit Account No. 04-1790. A duplicate copy of this sheet is enclosed.

December 16, 1999

Date

  
Michael L. Dunn

Attorney for Applicant(s)

Registration No. 25,330

P.O. Box 96

Newfane, New York 14108

Telephone: (716) 433-1661

MLD/cah

Enclosure

cc: M. DeLellis

**ORAL IMMUNOLOGY USING PLANT PRODUCT CONTAINING  
A NON-ENTERIC PATHOGEN ANTIGEN**

This is a Continuation-in-Part of U.S. Patent Application Serial Numbers 09/418,177, filed October 13, 1999 and 09/420,695, filed October 19, 1999.

Background of the Invention

Pathogenic microorganisms are known that do not raise a protective enteric immune response in mammals (non-enteric pathogens). Up to now it has been believed that protection against infection by such non-enteric pathogens could not be obtained by oral immunization, especially when antigens from the pathogens were used as opposed to complete live or attenuated pathogens.

Such pathogenic microorganisms usually invade by non-enteric routes, especially through punctures, abrasions, cuts or other breaches in the skin, e.g. through blood transfusion.

Examples of diseases caused by non-enteric pathogens are: hepatitis B, hepatitis C, hepatitis delta, yellow fever, Lassa fever, dengue hemorrhagic fever, rabies, tetanus, staphylococcus aureus infections, yaws, relapsing fever, rat bite fever, bubonic plague, typhoid fever and spotted fever.

As an example of the above, hepatitis B virus (HBV) is responsible for significant morbidity and mortality in spite of the availability of efficacious parenteral vaccines. In 1996 it was estimated that some 115 million people were infected with HBV. Mortality caused by this disease is estimated to be 1 million cases per year. In

developed countries such as the US, immunization rates for HBV remain below targeted objectives and there are over 300,000 new cases annually and 5,000 deaths each year as a result of HBV infection. In addition, a review of the prevalence of HBV infection in the US between 1976 and 1994 indicated that there was no significant decrease in HBV infection during that period, despite the availability of hepatitis B vaccine. Thus, in developed countries there is a need to improve the availability of and access to effective alternatives to current parenteral vaccines. This is even more important as the number of vaccines that are becoming part of childhood immunizations increases since there are practical considerations in how to safely and effectively administer the multiple antigens that are becoming part of the pediatric immunization schedule.

Another concern is that a significant proportion of the global morbidity and mortality is localized in developing countries where HBV is endemic. As an example, in rural Malawi evidence of HBV infection was found in 72% of women delivering in hospital and chronic carriage was 13%. In these settings, current parenteral vaccines are of limited availability because of the need for cold storage and the significant cost of the vaccines. While significant initiatives have begun to address the issue of how to provide hepatitis B vaccines to developing countries, alternative approaches are needed. Although immunization rates in developed countries may be on the increase, in the absence of an effective global immunization program for hepatitis B, there will continue to be importation of hepatitis B disease into developed countries from developing countries.

An alternative to parenteral immunizations for a few diseases are vaccines that can be delivered orally. As previously discussed, oral vaccines are generally not effective against non-enteric pathogens.

A specific approach to oral immunization has been proposed by expressing antigens in transgenic plant tissue followed by ingestion. This technique, in one step might have the potential to provide both a less complex manufacturing process and to provide the antigen in a “matrix” that would be suitable for oral immunization. In addition, plant tissues, such as potato tubers, have a distinct advantage in that vegetables, even in the raw state, have a long history of safety in the marketplace. Lastly, transgenic plant tissue expressing antigens that are delivered orally may have the added advantage that both humoral and mucosal immunity could be stimulated, resulting in the potential to protect mucosal surfaces more effectively than parenteral immunization alone might accomplish. Up to now, it has not been found that transgenic plant tissue expressing non-enteric pathogen antigenic material would be any more effective as an oral vaccine than direct oral intake of the purified antigen.

Plants expressing hepatitis B surface antigen (HBsAg) have in fact been developed but have also disappointingly been found to create little or unacceptably low immune responses in animals ingesting them even though HBsAg isolated from plants have been found to raise an immune response when administered parenterally. As used throughout this specification, HBsAg is intended to be exemplary and to represent other non-enteric pathogen antigens known to raise an immune response when parenterally administered.

### Brief Description of the Invention

Transgenic plants, e.g. potatoes, have been developed that express hepatitis B surface antigen, an antigen known to raise an immune response to hepatitis B when parenterally administered. Unfortunately it has been found that such an immune response is not raised to an acceptable level when the plant, e.g. potato, is simply fed to an animal.

It has, however, now been unexpectedly discovered that an immune response to non-enteric pathogen antigens, e.g., hepatitis B surface antigen ( HBsAg ) may be obtained when the antigen in a plant material is fed to the animal when the animal is immunoreceptive to the HBsAg. It has now been discovered that the animal may be made immunoreceptive to the non-enteric pathogen antigen, e.g. HBsAg, by administering the plant material containing the antigen in conjunction with a suitable adjuvant. The animal may also be immunoreceptive due to a prior , e.g. primary, immunization in which case an immune response to the non-enteric antigen, e.g. HBsAg may be boosted in the animal by feeding the animal the plant material containing the antigen. In such a case it has been found that no adjuvant is needed. An adjuvant may, however, be used with the goal of obtaining even higher immune response. For example, an animal, e.g. a human, that previously had a positive response to primary immunization against hepatitis B, can have a booster response to HBsAg by feeding the animal the antigen in a plant material. The plant material is a substance comprising a physiologically acceptable plant material from a plant (e.g. juice, pulp, leaves, stems, roots, fruit seeds, solids or the whole plant), especially

potatoes, containing hepatitis B surface antigen (HBsAg). The HBsAg in the plant results from expression by the plant of HBsAg due to genetic alteration.

### Detailed Description of the Invention

“Non-enteric pathogen antigen” (NEPA) means an antigen that will parenterally raise an immune response to a non-enteric pathogen.

HBsAg as used herein means hepatitis B surface antigen and is intended as an example of a non-enteric pathogen antigen.

The plant from which the desired plant material is obtained may be essentially any plant provided that the plant material contains the non-enteric pathogen antigen, e.g. HBsAg. Plants may be made to express HBsAg and other non-enteric pathogen antigens by transgenic alteration. Almost any plant suitable for ingestion can be altered to express HBsAg and other NEPA's, but the most preferred plants are food plants, e.g. plants that produce fruits, grains, and vegetables, such as bananas, potatoes and tomatoes. Especially preferred are plant materials that do not contain significant quantities of acid, e.g. tubers such as potatoes, since the acid in certain plant materials, such as tomatoes or citrus fruits, may cause degradation of the HBsAg. Further, plant materials that contain significant quantities of protease enzymes, e.g. papayas, may not be desirable since such enzymes could also degrade the HBsAg. A “significant” quantity as used herein, means a quantity that will cause antigen degradation to the extent that immune response is noticeably reduced.

Methods for genetic alteration of tobacco plants to express HBsAg and other antigens are already known to those skilled in the art, e.g. as described in Mason, et al.

“Expression of hepatitis B surface antigen in transgenic plants”, Proc. Natl. Acad. Sci USA, Vol. 89, pp. 11749, Dec. 1992. This article is incorporated by reference as background art. Tobacco is unfortunately not suitable for ingestion and is thus not physiologically acceptable. In accordance with the invention, it has been discovered that similar methods may be used to genetically alter other plants to express HBsAg and other NEPA's. Especially suitable plants, are plants of the family *solanaceae*, especially potatoes. Details for altering potatoes are given infra.

The plant used in accordance with the invention should contain at least 5 µg and preferably from about 7 µg to about 15 µg of HBsAg per gram of plant material to be ingested. The animal, e.g. a human, should ingest sufficient plant material to provide from about 10 to about 100 micrograms of hepatitis B surface antigen per kilogram of body weight. The animal, e.g. a human, will usually ingest sufficient plant material to provide a total from about 2 to about 5 grams of plant material per kilogram of body weight.

Immune response may be increased if a series of ingestions of the plant material is undertaken, e.g. a series of two or three with each ingestion being separated by at least five and preferably by at least about seven to fourteen days.

The plant material of the invention does not raise a significant immune response when administered orally in the absence of the required method steps of the invention, i.e. protection from the immune response. In accordance with the invention, the plant material containing HBsAg or other NEPA, must be orally administered either to a subject that has previously had a primary immunization, e.g. by parental injection or must be orally administered in conjunction with a suitable

adjuvant that effectively causes the HBsAg or other NEPA to raise a protective response. Prior to the present invention it was not predictable that an immune response to an NEPA such as HBsAg could be raised to a plant material containing NMPA when the plant material was ingested either by a subject having had a previous primary immunization or in conjunction with an adjuvant.

Adjuvants that may be effective include bacterial plasmid DNA, anti-HB antibody, oligodeoxynucleotides containing immunostimulatory CpG, modified cholera toxin (CT), modified *E. coli* heat stable lymphotoxin, lyophilic derivative of muramyl dipeptide (MDP-Lys (L18)), aluminum phosphate or aluminum sulfate, cytokines, or core protein of hepatitis C. A significant number of human subjects having previously received a primary immunization against hepatitis B show an immune booster response when treated in accordance with the method of the present invention, e.g. sixty percent or more of subjects. It must, however, be understood that a number of subjects may not obtain a measurable booster response, often for reasons not well understood. Among such reasons may be that the subject, even though previously receiving a primary immunizing treatment, may not in fact have had a strong primary immune response or there has been sufficient time lapse since the primary immunization that there are too few memory cells remaining in the subject. Similar results may occur with known vaccines, no matter how they are administered, i.e. there may be subjects that do not respond.

The invention may be illustrated by the following examples.

Animals were fed potatoes that expressed and contained HBsAg and anti-hepatitis B response was measured by enzyme immunoassay.



The potato was chosen as a preferred example of a plant that can be used in accordance with the invention for a number of reasons. In particular, the potato is relatively acid neutral when compared with other plant materials, especially certain fruits. Further, there have been a number of studies conducted on the potato with respect to its genetic character and possible transgenic modification. Most importantly, potatoes are a staple food and usual individual consumption is estimated at 1 to 100 kg per person per year worldwide. U.S. average individual consumption has been estimated at 36 kg per annum. In addition, potato is eaten in the U.S. as a raw vegetable and is cited in the Code of Federal Regulations [21 CFR 101.44(b)] among the 20 most frequently eaten raw vegetables. The specific cultivar of potato used to create the current HBV-EPV transgenic plants, in accordance with these specific examples, has also been used to create transgenic plants expressing other antigens. Raw, peeled potato from those plants as well as untransformed potatoes from the same parent line of potato have been safe and well tolerated in Phase I clinical trials for other expressed enteric antigens.

Methods for transforming plants to express HBsAg and other antigens are known to those skilled in the art, e.g. as described in U.S. Patents 5,484,719; 5,914,123 and 5,612,487 which are incorporated herein by reference as background art.

HBsAg has been previously expressed in transgenic tobacco plants (a member of the *solanaceae* (potato) family). In that system, HBsAg was expressed at a level of 0.01% of the total soluble leaf protein. HBsAg particles that were equivalent to those derived from recombinant yeast derived HBsAg were found in extracts of the leaf

tissues. When this material was administered intraperitoneally (i.p.) in combination with complete Freund's adjuvant (CFA) to mice, anti-HBS developed and there were no significant adverse events noted.

The lines of potatoes expressing HBsAg selected for use in accordance with these examples are transformed lines from *S. tuberosum* L. c.v. Frito-Lay 1607 HB-7. The transformed lines are designated FL-1607 HB-7 and HB114-16. To obtain these lines, the HBsAg gene from a pMT-SA clone of a Chinese adr isolate of HBV was inserted into transformation plasmid vectors (pHB-7 and pHB114) that were mobilized into *Agrobacterium tumefaciens* (LBA4404) that was then used to transform *Solanum tuberosum* L cv. "Frito-Lay 1607." The plasmid vectors used to construct the potato lines pHB-7 and pHB114-16 used in these examples both contain the gene for neomycin phosphotransferase (NPTII, also known as APH(3')II). This gene also becomes integrated into the potato genome and is expressed in the potato cells. *E. coli* derived NPTII has been shown to be biochemically equivalent to plant expressed NPTII. The *E. coli* derived NPTII degrades rapidly under conditions of simulated mammalian digestion and has been shown to cause no deleterious effects when purified protein was fed to mice at up to 5g/kg body weight. The transformed FL-1607 was cured of the *A. tumefaciens* and clonally propagated and the FL-1607 HB-7 and HB114-16 lines were selected for their high level of HBsAg expression. Extracts of the FL-1607 transformed lines were tested for HBsAg concentration by ELISA techniques. HB-7 averaged 1100 ng HBsAg per gram of tuber weight and HB114-16 averaged 8500 ng  $\pm$  2100 ng of HBsAg per gram of tuber weight.

In addition, the extracted HBsAg spontaneously forms virus like particles (VLPs) that sediment at the same density as yeast derived HBsAg VLPs. Electrophoretic mobility and western blot analysis indicates that the tuber expressed antigen is indistinguishable from yeast derived antigen.

The lines were clonally propagated to multiply the number of plants and potted in soil to produce the tubers used in the examples. The transformed lines were maintained by *in vitro* clonal propagation.

The untransformed parent potato line, FL-1607, was maintained by clonal propagation and potted to produce tubers that were used as the placebo control. The tissues from these tubers do not express any proteins that are reactive with reagents to detect HBsAg.

#### Example 1

BALB/c mice were fed either peeled HB-7 potato slices or control non-transformed potatoes. Each group of mice was given three 5 gm feedings of potato on days 0, 7 and 14. The B subunit of cholera toxin (CT) (Sigma) was used as an oral adjuvant. Ten µg of the adjuvant was placed on the potato slices (both experimental and control) and consumed by the animals in conjunction with the antigen. The animals fed HB-7 therefore received an average of 5.5 µg HBsAg per feeding, or a total average dose of 16.5 µg HBsAg over the 3 feedings provided.

Mice fed HB-7 developed serum IgM and IgG responses that were specific to HBsAg, whereas the group of animals fed control non-transformed potatoes failed to make any antibodies. After the third feeding an immune response was observed that peaked at around 70mIU/ml. After a single i.p. inoculation of 0.5 µg of yeast derived

recombinant HBsAg (rHBsAg) in alum (a normally subimmunogenic dose) a strong secondary response was observed that peaked at around 1700mIU/ml. This response was predominantly IgG. No primary or secondary response was seen in the control mice fed non-transgenic potato and CT. Without the oral adjuvant, there was no significant response to HBsAg.

## Example 2

Further experiments have used the Frito-Lay 1607 HB114-16 line. In this line expression is driven from the 35S promoter and average tuber expression in the lot used for these experiments was 8.37  $\mu\text{g}$  HBsAg/gm wet weight of tuber.

Groups of BALB/c mice (5/group) were fed either with HB114-16 or with control non-transgenic potato. In both cases 10  $\mu\text{g}$  CT was added to the potato. The feeding was repeated one and two weeks later. The total average dose to each mouse of HBsAg in the transgenic potato was 125.55  $\mu\text{g}$  over the 3-week period. Then, at the later of 70 days following the first feed or at 3-6 weeks after the initial immune response had returned to baseline levels, the mice were immunized with a sub-immunogenic ( 0.5  $\mu\text{g}$  ) dose of rHBsAg (Merck) delivered in aluminum adjuvant by subcutaneous (s.c.) injection.

At these dose levels an initial immune response was seen immediately after the second feeding. This immune response continued to rise and peaked at around 6 weeks at 100mIU/ml. A titer of only 10mIU/ml in a human after three doses of a current licensed injectable hepatitis B vaccine is considered to reflect successful immunization. The response returned to baseline at 13 weeks and at 16 weeks the animals were given the booster dose of rHBsAg. This led to an immediate rise in

immune titer to >3000mIU/ml, which remained over 1000mIU/ml for the remainder of the experiment (40 weeks). See Figure 1. This established that the primary immunization generated antigen specific immune memory cells that were rapidly and strongly recalled upon secondary boosting.

The control animals for this experiment that were given non-transgenic potato + CT did not develop an immune response to HBsAg and upon secondary challenge with the subimmunogenic dose, as described above, no secondary response was seen ( Figure 2 ) establishing the specificity of the results shown in Figure 1. Controls given transgenic potato without CT only developed a low level, i.e. 10 mIU/ml titer for a primary response that returned to baseline in only one week. Further challenge with the subimmunogenic dose as described above only gave a secondary response of 50mIU/ml and return to only 10 mIU/ml in only two weeks.

### Example 3

The transgenic potato has also been used to boost a pre-existing sub-immunogenic dose of rHBsAg in mice. In this experiment groups of BALB/c mice (5/group) were immunized with a sub-immunogenic dose of rHBsAg (Merck) delivered s.c. in alum. 5 weeks later each mouse was fed either with HB114-16 or with control non-transgenic potato. In both cases 10 µg CT was added to the potato. The feeding was repeated one and two weeks later. The total average dose to each mouse was 125.55 µg over the 3-week period.

A secondary response developed that had started to appear at the time of the third feeding and which rose to approximately 1000mIU/ml 11 weeks after the initial

priming immunization before declining. See Figure 3. In a control group no immune response developed in the group fed the non-transgenic potato. See Figure 4.

#### Example 4

Forty two human subjects testing free of HIV and being previously immunized with a commercial HB vaccine and after an extended time having anti-HBsAg titers below 115 mIU/ml, were fed potatoes containing HBsAg or an HBsAg free potato control in a randomized double blind study. When the code was broken, it was determined that Group 1 was a control group that received three doses of 100 grams of nontransgenic potato FL-1607. Group 2 received two doses of 100 grams each of transgenic potato FL-1607 HB114-16 and one dose of nontransgenic FL-1607 potato. Group 3 received three doses of 100 grams each of transgenic potato FL-1607 HB114-16.

Available pre-clinical data indicate that (1) on a weight basis, mice freely consume of up to 25% of their body weight in potato without evidence of toxicity and (2) a total of about 16  $\mu$ g dose of HBsAg in about 15 gm of potato is immunogenic in a primary series with an oral adjuvant. The available clinical data with other potato vaccines indicate that (1) consumption of 100 gm of raw potato is generally well tolerated and (2) on a weight basis, 100 gm consumed by a 70 kg person would represent 0.14% of body weight. This amount is approximately 178-fold less than has been consumed, by weight, in mice in pre-clinical experiments.

Thus, in the example for humans, 100 to 110 gm of potato was ingested by volunteers per dose. The clinical lot scheduled for use in this study contained  $8.5 \pm 2.1$   $\mu$ g of HBsAg per gm of potato. Subjects who received two 100 gm doses of

transgenic potato received a total dose of 1,280 to 2,120 µg of HBsAg and subjects receiving three doses received a total of 1,920 to 3,180 µg of HBsAg over the course of 28 days.

On each day of dosing (days 0, 14 and 28) the appropriate number of potatoes for each group (placebo and control) were separately removed and processed into individual 100 to 110 gm doses by pharmacy personnel using clean techniques. Briefly, selected potatoes were washed, peeled, diced and placed into an ice-cold water bath. Peeling of the potatoes was done to remove the skin that contains the alkaloid solanine. This alkaloid can cause abdominal discomfort or nausea and may cause a bitter taste. Following peeling and dicing, 100 to 110 gm doses of potato was weighed out for each study subject according to group assignment and Subject Identification Number (SID). Peels and any unused portions of potatoes were collected and processed for destruction. Aliquots of potato for each study subject was kept under water to prevent browning from oxidation between the time the potato was diced until the study subject consumed it. An appropriate sample of processed potato from each group at each feeding was retained and frozen for further processing to verify antigen content.

The subjects were tested for anti-HBsAg titer on the days shown in Tables 1, 2, and 3. The results clearly show an increased response to the administered HBsAg NEPA antigen as a result of ingesting of the genetically transformed potatoes. Over 60 percent of the subjects receiving three doses of potatoes containing HBsAg NMPA showed a significant increase in immune response. The tables clearly indicate that, in many cases, ingesting of plant material containing genetically expressed HBsAg

NEPA can act as an effective booster for primary HB vaccination. None of the control subjects that received three doses of non-transgenic control potatoes had any change in antibody titer over the entire course of the observation.



**TABLE 1**

**Group 1 (Received 3 doses of Nontransgenic potato tuber)**

**Titer (lm/ml)**

<b>Volunteers</b>	<b>Day 0</b>	<b>Day 7</b>	<b>Day 14</b>	<b>Day 21</b>	<b>Day 28</b>	<b>Day 35</b>	<b>Day 42</b>	<b>Day 56</b>	<b>Day 70</b>
1	63	51	56	67	69	74	88	89	93
2	66	78	52	62	54	74	67	69	80
3	12	9	12	18	18	16	17	19	16
4	34	28	24	32	33	29	34	33	30
5	104	99	83	110	120	100	99	92	92
6	72	64	73	74	78	78	63	57	62
7	17	14	12	12	2	5	10	9	6
8	0	0	0	1	0	0	0	7	11
9	9	11	12	11	8	7	9	9	8

**TABLE 2**

**Group 2 (Received 2 doses of Transgenic & 1 dose of Nontransgenic potato tuber)**

**Titer (mIU/ml)**

<b>Volunteers</b>	<b>Day 0</b>	<b>Day 7</b>	<b>Day 14</b>	<b>Day 21</b>	<b>Day 28</b>	<b>Day 35</b>	<b>Day 42</b>	<b>Day 56</b>	<b>Day 70</b>
1	29	29	29	29	29	29	47	93	105
2	8	15	27	49	41	40	73	79	66
3	170	161	158	144	130	144	144	132	178
4	32	32	31	34	33	23	23	42	60
5	43	37	46	77	69	85	85	78	81
6	67	37	47	57	80	89	77	73	75
7	11	7	114	114	136	176	191	200	136
8	104	126	262	269	318	313	357	390	445
9	33	26	22	21	21	25	25	29	31
10	107	92	96	89	93	83	95	90	100
11	21	22	55	112	120	219	395	458	462
12	65	68	66	63	89	103	137	258	304
13	20	24	18	15	12	12	15	20	17
14	0	0	0	0	0	0	0	0	0
15	97	93	112	109	128	294	454	432	347
16	26	34	197	330	353	360	707	863	790
17	13	15	15	14	11	11	17	17	18

**TABLE 3**

**Group 3(Received 3 doses of Transgenic potato tuber)**

**Titer (mlU/ml)**

<b>Volunteers</b>	<b>Day 0</b>	<b>Day 7</b>	<b>Day 14</b>	<b>Day 21</b>	<b>Day 28</b>	<b>Day 35</b>	<b>Day 42</b>	<b>Day 56</b>	<b>Day 70</b>
1	17	20	70	140	269	428	401	463	496
2	94	87	100	99	88	79	87	88	99
3	33	34	32	33	27	34	31	32	34
4	9	9	53	74	74	85	64	61	60
5	20	41	57	84	452	475	897	652	745
6	85	76	496	1212	3058	3572	4152	4526	4788
7	13	19	19	15	28	14	20	21	24
8	120	236	282	390	605	667	1583	1717	1712
9	72	77	137	270	349	523	1098	1226	1225
10	85	76	84	74	111	215	175	163	108
11	40	35	39	71	119	122	330	430	342
12	56	51	59	85	252	407	520	745	834
13	115	213	511	1054	1964	3069	2966	3449	3266
14	0	0	0	0	0	0	0	0	0
15	9	11	14	13	13	18	11	15	18
16	0	0	0	0	0	0	0	0	0

## WHAT IS CLAIMED IS:

1. A method for providing an immune response to a non-enteric pathogen antigen (NEPA), in an animal made immunoreceptive to the NEPA, by feeding the immunoreceptive animal with a substance comprising a physiologically acceptable plant material containing the NEPA.
2. The method of Claim 1 where the NEPA is hepatitis B surface antigen (HBsAg).
3. The method of Claim 1 wherein the animal is made immunoreceptive to the NEPA by feeding the substance to the animal in conjunction with an adjuvant that renders the animal immunoreceptive to the NEPA.
4. The method of Claim 3 where the NEPA is HBsAg.
5. The method of Claim 1 wherein the animal is human.
6. The method of Claim 5 wherein the plant material is from a plant that has been genetically altered to express said antigen.

7. The method of Claim 6 wherein the human ingests sufficient plant material to provide from about 10 to about 100 micrograms of NEPA per kilogram of body weight of the human.

8. The method of Claim 7 wherein the human ingests sufficient plant material to provide from about 2 to about 5 grams of plant material per kilogram of body weight of the human.

9. The method of Claim 8 wherein the human ingests said plant material a plurality of different times, said times being separated from each other by at least 5 days.

10. The method of Claim 9 wherein the plurality of times is three times.

11. The method of Claim 10 wherein the plant material is a material from a plant of the family *solanaceae*.

12. The method of Claim 11 wherein the plant is a potato.

## ORAL IMMUNOLOGY USING PLANT PRODUCT CONTAINING A NON-ENTERIC PATHOGEN ANTIGEN

### Abstract of the Disclosure

A method for obtaining an immune response to a non-enteric pathogen antigen (NEPA) such as hepatitis B surface antigen (HBsAg) by feeding the antigen in a plant material to an animal that is immunoreceptive to the NEPA. It has now been discovered that the animal may be made immunoreceptive to the NEPA such as HBsAg by administering the plant material containing the NEPA in conjunction with a suitable adjuvant. The plant material is a substance comprising a physiologically acceptable plant material, especially potatoes, containing the NEPA, e.g. hepatitis B surface antigen (HBsAg). The NEPA, e.g. HBsAg in the plant results from expression by the plant of the NEPA due to genetic alteration.

**DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION**

**English Language Declaration**

**Express Mail Mailing Label No. EJ870782822US  
RPP:156B US**

**As a below named inventor, I hereby declare that:**

**My residence, post office address and citizenship are as stated below next to my name,**

**I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled**

**ORAL IMMUNOLOGY USING PLANT PRODUCT CONTAINING  
A NON-ENTERIC PATHOGEN ANTIGEN**

**the specification of which**

**(check one)**

**☒ is attached hereto.**

**☐ was filed on \_\_\_\_\_, as Application Serial No. \_\_\_\_\_  
and was amended on \_\_\_\_\_**

**I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.**

**I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, code of Federal Regulations, Section 1.56.**

**I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:**

# ENGLISH LANGUAGE DECLARATION

## Prior Foreign Application(s)

## Priority Claimed

(Number)	(Country)	(Day/Month/Year Filed)				
			[ ]	[ ]	[ ]	
			Yes	No		

(Number)	(Country)	(Day/Month/Year Filed)				
			[ ]	[ ]	[ ]	
			Yes	No		

(Number)	(Country)	(Day/Month/Year Filed)				
			[ ]	[ ]	[ ]	
			Yes	No		

**I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:**

09/418,177	October 13, 1999	Pending
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)
09/420,695	October 19, 1999	Pending
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

**I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.**



ENGLISH LANGUAGE DECLARATION

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application, including all divisionals and continuations thereof, and transact all business in the Patent and Trademark Office connected therewith. (List name and registration number)

Michael L. Dunn, Registration No. 25,330

Howard M. Ellis, Registration No. 25,856

**SEND CORRESPONDENCE TO:**

Dunn & Associates  
P.O. Box 96  
Newfane, New York 14108

**DIRECT ALL TELEPHONE CALLS TO:**

Michael L. Dunn, Telephone No. (716) 433-1661

Full name of sole or first inventor

Yasmin Thanavala

Inventor's signature

Date

Residence

150 Presidio Place, Williamsville, New York 14221

Citizenship

India

Post Office Address

Same as above

Full name of second joint inventor, if any

Charles Joel Arntzen

Inventor's signature

Date

Residence

1005 Highland Road, Ithaca, New York 14850-1447

Citizenship

United States of America

Post Office Address

Same as above